Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
EDQM
0
USP
0
JP
0
Others
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
US Medicaid
NA
Annual Reports
NA
Regulatory FDF Prices
NA
0
API
0
FDF
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. 2092925-89-6
2. Palazestrant [inn]
3. Vu35km56q4
4. Schembl20528170
5. Us11672785, Compound B
6. Bdbm605421
7. Hy-148789
8. Cs-0641077
9. (1r,3r)-2-(2-fluoro-2-methylpropyl)-3-methyl-1-{4-[(1-propylazetidin-3- Yl)oxy]phenyl}-2,3,4,9-tetrahydro-1h-pyrido[3,4-b]indole
10. 1h-pyrido[3,4-b]indole, 2-(2-fluoro-2-methylpropyl)-2,3,4,9-tetrahydro-3-methyl-1-[4-[(1-propyl-3-azetidinyl)oxy]phenyl]-, (1r,3r)-
| Molecular Weight | 449.6 g/mol |
|---|---|
| Molecular Formula | C28H36FN3O |
| XLogP3 | 5.8 |
| Hydrogen Bond Donor Count | 1 |
| Hydrogen Bond Acceptor Count | 4 |
| Rotatable Bond Count | 7 |
| Exact Mass | g/mol |
| Monoisotopic Mass | g/mol |
| Topological Polar Surface Area | 31.5 |
| Heavy Atom Count | 33 |
| Formal Charge | 0 |
| Complexity | 645 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 2 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Drugs in Development
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Digital Content
NEWS #PharmaBuzz
ABOUT THIS PAGE
59
PharmaCompass offers a list of Palazestrant API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Palazestrant manufacturer or Palazestrant supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Palazestrant manufacturer or Palazestrant supplier.
PharmaCompass also assists you with knowing the Palazestrant API Price utilized in the formulation of products. Palazestrant API Price is not always fixed or binding as the Palazestrant Price is obtained through a variety of data sources. The Palazestrant Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Palazestrant manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Palazestrant, including repackagers and relabelers. The FDA regulates Palazestrant manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Palazestrant API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Palazestrant supplier is an individual or a company that provides Palazestrant active pharmaceutical ingredient (API) or Palazestrant finished formulations upon request. The Palazestrant suppliers may include Palazestrant API manufacturers, exporters, distributors and traders.
Palazestrant Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Palazestrant GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Palazestrant GMP manufacturer or Palazestrant GMP API supplier for your needs.
A Palazestrant CoA (Certificate of Analysis) is a formal document that attests to Palazestrant's compliance with Palazestrant specifications and serves as a tool for batch-level quality control.
Palazestrant CoA mostly includes findings from lab analyses of a specific batch. For each Palazestrant CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Palazestrant may be tested according to a variety of international standards, such as European Pharmacopoeia (Palazestrant EP), Palazestrant JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Palazestrant USP).
